Can we prevent acute kidney injury?

Critical Care Medicine

Volumn 36, Issue SUPPL. 4, 2008, Pages

  Venkataraman, Ramesh ^a  

^a APOLLO HOSPITALS   (India)

Author keywords

Acute kidney injury; Acute renal failure; Diuretics; Dopamine; Fenoldopam; N acetylcysteine; Prevention; Radiocontrast nephropathy; Theophylline

Indexed keywords

ACETYLCYSTEINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANARITIDE; ATRIAL NATRIURETIC FACTOR; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; FENOLDOPAM MESILATE; FUROSEMIDE; IODIXANOL; IOPAMIDOL; ISRADIPINE; THEOPHYLLINE;

ACUTE GRAFT REJECTION; BLOOD VOLUME; CLINICAL TRIAL; DIALYSIS; FEBRILE NEUTROPENIA; HUMAN; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY PERFUSION; KIDNEY TUBULE DISORDER; MEAN ARTERIAL PRESSURE; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 41649120004     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318168c74a     Document Type: Review

References (66)

1. Bellomo R, Ronco C, Kellum JA, et al: Acute renal failure: Definition, outcome measures, animal models, fluid therapy and information technology needs. The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-R212
2. Hoste EA, Clermont G, Kersten A, et al: RIFLE criteria for acute kidney injury is associated with hospital mortality in critical ill patients: A cohort analysis. Crit Care 2006; 10:R73
3. Uchino S, Bellomo R, Goldsmith D: An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006; 34:1913-1917
4. Uchino S, Kellum JA, Bellomo R, et al: Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294:813-818
5. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome: The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301-1308
6. Kellum JA, Angus DC: Patients are dying of acute renal failure. Crit Care Med 2002; 30:2156-2157
7. Metnitz PG, Krenn CG, Steltzer H, et al: Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002; 30:2051-2058
8. Ostermann M, Chang RW: Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007; 35:1837-1843
9. Chertow GM, Levy EM, Hammermeister KE, et al: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998; 104:343-348
10. Hoste EA, Lameire NH, Vanholder RC, et al: Acute renal failure in patients with sepsis in a surgical ICU: Predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003; 14:1022-1030
11. Solomon R, Werner C, Mann D, et al: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331:1416-1420
12. Better OS, Rubinstein I: Management of shock and acute renal failure in casualties suffering from the crush syndrome. Ren Fail 1997; 19:647-653
13. Trivedi HS, Moore H, Nasr S, et al: A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93:C29-C34
14. Mueller C, Buerkle G, Buettner HJ: Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162:329-336
15. Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004; 291:2328-2334
16. Kellum JA, Pinsky MR: Use of vasopressor agents in critically ill patients. Curr Opin Crit Care 2002; 8:236-241
17. Langenberg C, Bellomo R, May C, et al: Renal blood flow in sepsis. Crit Care 2005; 9:R363-R374
18. Malbrain ML, Chiumello D, Pelosi P, et al: Incidence and prognosis of intraabdominal hypertension in a mixed population of critically ill patients: A multiple-center epidemiological study. Crit Care Med 2005; 33:315-322
19. Swan SK: Aminoglycoside nephrotoxicity. Semin Nephrol 1997; 17:27-33
20. Barza M, Ioannidis JP, Cappelleri JC, et al: Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ 1996; 312:338-345
21. Hatala R, Dinh T, Cook DJ: Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med 1996; 124:717-725
22. Hatala R, Dinh TT, Cook DJ: Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review. Clin Infect Dis 1997; 24:810-815
23. Harbarth S, Pestotnik SL, Lloyd JF, et al: The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111:528-534
24. White MH, Bowden RA, Sandler ES, et al: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27:296-302
25. Walsh TJ, Finberg RW, Arndt C, et al: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia: National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764-771
26. Barrett BJ, Carlisle EJ: Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188:171-178
27. Aspelin P, Aubry P, Fransson SG, et al: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348:491-499
28. Jo SH, Youn TJ, Koo BK, et al: Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: The RECOVER study: A randomized controlled trial. J Am Coll Cardiol 2006; 48:924-930
29. Barrett BJ, Katzberg RW, Thomsen HS, et al: Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: A double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006; 41:815-821
30. McCullough PA, Bertrand ME, Brinker JA, et al: A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006; 48:692-699
31. Solomon R: The role of osmolality in the incidence of contrast-induced nephropathy: A systematic review of angiographic contrast media in high risk patients. Kidney Int 2005; 68:2256-2263
32. Pannu N, Wiebe N, Tonelli M: Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006; 295:2765-2779
33. Lameire NH: The pathophysiology of acute renal failure. Crit Care Clin 2005; 21:197-210
34. Schrier RW, Wang W: Acute renal failure and sepsis. N Engl J Med 2004; 351:159-169
35. Kellum JA: The use of diuretics and dopamine in acute renal failure: A systematic review of the evidence. Crit Care 1997; 1:53-59
36. Ho KM, Sheridan DJ: Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006; 333:420
37. Mehta RL, Pascual MT, Soroko S, et al: Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288:2547-2553
38. Uchino S, Doig GS, Bellomo R, et al: Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32:1669-1677
39. Kellum JA, Decker JM: Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med 2001; 29:1526-1531
40. Marik PE: Low-dose dopamine: A systematic review. Intensive Care Med 2002; 28:877-883
41. Friedrich JO, Adhikari N, Herridge MS, et al: Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142:510-524
42. Bellomo R, Chapman M, Finfer S, et al: Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356:2139-2143
43. Halpenny M, Rushe C, Breen P, et al: The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol 2002; 19:32-39
44. Stone GW, McCullough PA, Tumlin JA, et al: Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA 2003; 290:2284-2291
45. Morelli A, Ricci Z, Bellomo R, et al: Prophylactic fenoldopam for renal protection in sepsis: A randomized, double-blind, placebo-controlled pilot. Crit Care Med 2005; 33:2451-2456
46. Landoni G, Biondi-Zoccai GG, Tumlin JA, et al: Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: A meta-analysis of randomized clinical trials. Am J Kidney Dis 2007; 49:56-68
47. Allgren RL, Marbury TC, Rahman SN, et al: Anaritide in acute tubular necrosis: Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997; 336:828-834
48. Kurnik BR, Allgren RL, Genter FC, et al: Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998; 31:674-680
49. Lewis J, Salem MM, Chertow GM, et al: Atrial natriuretic factor in oliguric acute renal failure: Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000; 36:767-774
50. Sward K, Valsson F, Odencrants P, et al: Recombinant human atrial natriuretic peptide in ischemic acute renal failure: A randomized placebo-controlled trial. Crit Care Med 2004; 32:1310-1315
51. Schrier RW, Arnold PE, Van Putten VJ, et al: Cellular calcium in ischemic acute renal failure: Role of calcium entry blockers. Kidney Int 1987; 32::313-321
52. Epstein M: Calcium antagonists and the kidney: Future therapeutic perspectives. Am J Kidney Dis 1993; 21(6 Suppl 3):16-25
53. Epstein M, De Michelli AG, Forster H: Natriuretic effects of calcium antagonists in humans: A review of experimental evidence and clinical data. Cardiovasc Drug Rev 1991; 9:399-413
54. van Riemsdijk IC, Mulder PG, de Fijter JW, et al: Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: A double-blind, randomized, placebo-controlled, multi-center study. Transplantation 2000; 70:122-126
55. Shilliday IR, Sherif M: Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients. Cochrane Database Syst Rev 2004; 1:CD003421
56. Erley CM, Duda SH, Schlepckow S, et al: Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994; 45:1425-1431
57. Erley CM, Duda SH, Rehfuss D, et al: Prevention of radiocontrast-media- induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999; 14:1146-1149
58. Kolonko A, Wiecek A, Kokot F: The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998; 11:151-156
59. Ix JH, McCulloch CE, Chertow GM: Theophylline for the prevention of radiocontrast nephropathy: A meta-analysis. Nephrol Dial Transplant 2004; 19:2747-2753
60. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89:356-358
61. Durham JD, Caputo C, Dokko J, et al: A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62:2202-2207
62. Tepel M, van der Giet M, Schwarzfeld C, et al: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343:180-184
63. Pannu N, Manns B, Lee H, et al: Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004; 65:1366-1374
64. Hoffmann U, Fischereder M, Kruger B, et al: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15:407-410
65. Deray G: Dialysis and iodinated contrast media. Kidney Int Suppl 2006; 100:S25-S29
66. Marenzi G, Marana I, Lauri G, et al: The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349:1333-1340